Drugs最新文献_第7页

Crovalimab: First Approval. Crovalimab：首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-14 DOI: 10.1007/s40265-024-02032-5

Sohita Dhillon

{"title":"Crovalimab: First Approval.","authors":"Sohita Dhillon","doi":"10.1007/s40265-024-02032-5","DOIUrl":"10.1007/s40265-024-02032-5","url":null,"abstract":"Crovalimab (®; PiaSky) is a humanized, anti-complement component C5 (anti-C5) recycling monoclonal antibody developed by Chugai Pharmaceutical, in collaboration with Roche, which is being investigated for the treatment of complement-mediated diseases, including paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome, lupus nephritis and sickle cell disease. Crovalimab targets C5, inhibiting its cleavage to C5a and C5b, thus blocking the terminal complement pathway and preventing intravascular haemolysis in PNH. Crovalimab is designed to bind to the antigen repeatedly, resulting in sustained complement inhibition at a lower dosage, and allowing for once-monthly subcutaneous administration. In February 2024, subcutaneous crovalimab received its first approval in China for the treatment of adolescents and adults (aged ≥ 12 years) with PNH who have not been previously treated with complement inhibitors. Crovalimab has since been approved in Japan in March for use in the treatment of PNH, including in treatment-naïve and previously treated patients. Crovalimab is also under regulatory review for the treatment of naïve and previously treated patients with PNH in multiple countries, including the USA and the European Union. This article summarizes the milestones in the development of crovalimab leading to this first approval in China for the treatment of PNH.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding Differences in Sex-Based Outcomes with Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. 了解经皮冠状动脉介入术后双联抗血小板疗法基于性别的疗效差异。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-29 DOI: 10.1007/s40265-024-02041-4

Ibrahim Akin, Nazha Hamdani, Ibrahim El-Battrawy

引用次数: 0

Resmetirom: First Approval. Resmetirom：首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-21 DOI: 10.1007/s40265-024-02045-0

Susan J Keam

引用次数: 0

Cefepime/Enmetazobactam: First Approval. 头孢吡肟/恩美唑巴坦：首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-18 DOI: 10.1007/s40265-024-02035-2

Susan J Keam

引用次数: 0

Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis. 经皮冠状动脉介入术后基于性别的双抗血小板疗法结果：配对和网络 Meta 分析

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-29 DOI: 10.1007/s40265-024-02034-3

Thomas A Agbaedeng, Jean Jacques Noubiap, Kirsty A Roberts, Derek P Chew, Peter J Psaltis, Azmeraw T Amare

{"title":"Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis.","authors":"Thomas A Agbaedeng, Jean Jacques Noubiap, Kirsty A Roberts, Derek P Chew, Peter J Psaltis, Azmeraw T Amare","doi":"10.1007/s40265-024-02034-3","DOIUrl":"10.1007/s40265-024-02034-3","url":null,"abstract":"Background: Although dual antiplatelet therapy (DAPT) improves the outcomes of patients undergoing percutaneous coronary intervention (PCI), sex-specific differences in efficacy and safety of DAPT remain unresolved. We compared sex differences for DAPT outcomes and DAPT durations (1-3 months [short-term], 6 months [mid-term], and >12 months [extended] vs. 12 months).Methods: We searched databases through 31 December 2023 for trials reporting DAPT after PCI. The endpoints were major adverse cardiovascular and cerebrovascular events (MACCE), net adverse clinical and cerebrovascular events (NACCE), and any bleeding. Extracted data were pooled in a frequentist network and pairwise, random-effects meta-analysis.Results: Twenty-two trials (99,591 participants, 25.2% female) were included. Female sex was significantly associated with a higher 1-year MACCE risk (hazard ratio 1.14 [95% confidence interval 1.02-1.28]) and bleeding (1.13 [1.00-1.28]), but not NACCE (1.12 [0.96-1.31]). In sub-analyses, the association between female sex and MACCE was related to use of clopidogrel as the second antiplatelet agent (1.11 [1.03-1.20]), whereas higher bleeding events were related to newer P2Y12 inhibitors (P2Y12i) (1.58 [1.01-2.46]). For DAPT duration, short-term DAPT followed by P2Y12i monotherapy was non-inferior for MACCE in females and males (0.95 [95% CI 0.83-1.10; and 0.96 [0.80-1.16]) but tended to be superior in males for NACCE versus 12-month DAPT (0.96 [0.91-1.01]); mid-term DAPT tended to be associated with a lower bleeding risk in males (0.43 [0.17-1.09]).Conclusions: Female sex is associated with higher MACCE and bleeding when newer P2Y12i agents are used. Short-term DAPT followed by P2Y12i monotherapy is safe and effective in both sexes undergoing PCI.Clinical trials registration: PROSPERO ID: CRD42021278663.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141161341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Potential of Lipoprotein(a) Inhibitors. 脂蛋白（a）抑制剂的治疗潜力。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-06-08 DOI: 10.1007/s40265-024-02046-z

Stephen J Nicholls

引用次数: 0

Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned. 针对系统性红斑狼疮的干扰素信号：经验教训。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-28 DOI: 10.1007/s40265-024-02043-2

Sarah A Jones, Eric F Morand

{"title":"Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned.","authors":"Sarah A Jones, Eric F Morand","doi":"10.1007/s40265-024-02043-2","DOIUrl":"10.1007/s40265-024-02043-2","url":null,"abstract":"The development of new medicines for systemic lupus erythematosus (SLE) has not addressed unmet clinical need, with only three drugs receiving regulatory approval for SLE in the last 60 years, one of which was specifically licensed for lupus nephritis. In the last 20 years it has become clear that activation of type 1 interferons (IFN) is reproducibly detected in the majority of SLE patients, and the actions of IFN in the immune system and on target tissues is consistent with a pathogenic role in SLE. These findings led to considerable drug discovery activity, first with agents directly targeting IFN family cytokines, with results that were encouraging but underwhelming. In contrast, targeting the type I IFN receptor with the monoclonal antibody anifrolumab, thereby blocking all IFN family members, was effective in a phase II clinical trial. This led to a pair of phase III trials, one of which was negative and the other positive, reflecting the difficulty of obtaining outcomes from trials in this complex disease. Nonetheless, the balance of evidence resulted in approval of anifrolumab in multiple jurisdictions from 2021 onwards. Multiple approaches to targeting the type 1 IFN pathway have subsequently had positive phase II clinical trials, including antibodies targeting cells that produce IFN, and small molecules targeting the receptor kinase TYK2, required for IFN signalling. Despite multiple hurdles, it is clear that IFN targeting in SLE is here to stay. The story of IFN-targeting therapy in SLE has lessons for drug development overall in this disease.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141161399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions. 产后抑郁症：影响和当前治疗方案的临床回顾。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-30 DOI: 10.1007/s40265-024-02038-z

Cindy-Lee Dennis, Daisy R Singla, Hilary K Brown, Katarina Savel, Crystal T Clark, Sophie Grigoriadis, Simone N Vigod

{"title":"Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions.","authors":"Cindy-Lee Dennis, Daisy R Singla, Hilary K Brown, Katarina Savel, Crystal T Clark, Sophie Grigoriadis, Simone N Vigod","doi":"10.1007/s40265-024-02038-z","DOIUrl":"10.1007/s40265-024-02038-z","url":null,"abstract":"Depression during the first year postpartum (postpartum depression) impacts millions of women and their families worldwide. In this narrative review, we provide a summary of postpartum depression, examining the etiology and consequences, pharmacological and psychological treatments, and potential mechanisms of change and current barriers to care. Psychological treatments are effective and preferred by many perinatal patients over medications, but they often remain inaccessible. Key potential mechanisms underlying their effectiveness include treatment variables (e.g., dosage and therapeutic alliance) and patient behaviors (e.g., activation and avoidance and emotional regulation). Among pharmacological treatments, the selective serotonin reuptake inhibitor (SSRI) sertraline is generally the first-line antidepressant medication recommended to women in the postpartum period due to its minimal passage into breastmilk and the corresponding decades of safety data. Importantly, most antidepressant drugs are considered compatible with breastfeeding. Neurosteroids are emerging as an effective treatment for postpartum depression, although currently this treatment is not widely available. Barriers to widespread access to treatment include those that are systematic (e.g., lack of specialist providers), provider-driven (e.g., lack of flexibility in treatment delivery), and patient-driven (e.g., stigma and lack of time for treatment engagement). We propose virtual care, task-sharing to non-specialist treatment providers, and collaborative care models as potential solutions to enhance the reach and scalability of effective treatments to address the growing burden of postpartum depression worldwide and its negative impact on families and society.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ensitrelvir Fumaric Acid: First Approval. Ensitrelvir 富马酸：首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-25 DOI: 10.1007/s40265-024-02039-y

Yahiya Y Syed

引用次数: 0

Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. 更正：鲁索利替尼乳膏 1.5%：非节段型白癜风综述。

IF 13 1区医学

Drugs Pub Date : 2024-06-01 Epub Date: 2024-05-29 DOI: 10.1007/s40265-024-02055-y

Connie Kang

引用次数: 0